Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PAROXETINE HCL

All products: general benefit

Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable

  • Citalopram (Celexa): general benefit, Not a benefit
  • Escitalopram (Cipralex MELTZ): general benefit, Not a benefit
  • Fluoxetine (Prozac): general benefit, Not a benefit
  • Fluvoxamine (Luvox): general benefit
  • Sertraline (Zoloft): general benefit
  • Amitriptyline (Elavil): general benefit

17 more in the class list below

Paxil · DIN 01940473 · 30mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-03-10 — choose a marketed DIN from the same-category list.Discontinued 2026-03-10 · checked 2026-09-20
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-03-10 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-03-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Paxil (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Paxil · DIN 01940473 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-03-10 · brand PAXIL TAB 30MG · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 30 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3453 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14006 · Verify on the e-Formulary ↗ (DIN 01940473)

Source record
DIN 01940473: Paxil Raw flags: sec3=Y Item: 281604079; group id 467; item number 1177; lccId None; manufacturer id GSK Source form: Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $2.7080; ministry $0.3453 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01940473 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14006
Interchangeable products
AG-Paroxetine · DIN 02475553 · $0.3453 Apo-Paroxetine · DIN 02240909 · $0.3453 Auro-Paroxetine · DIN 02383292 · $0.3453 Jamp Paroxetine Tablets · DIN 02507803 · $0.3453 Jamp-Paroxetine · DIN 02368889 · $0.3453 M-Paroxetine · DIN 02467429 · $0.3453 Mar-Paroxetine · DIN 02411962 · $0.3453 Mint-Paroxetine · DIN 02421399 · $0.3453 NRA-Paroxetine · DIN 02479788 · $0.3453 PMS-Paroxetine · DIN 02247752 · $0.3453 Paroxetine · DIN 02282860 · $0.3453 Paroxetine · DIN 02388243 · $0.3453 Sandoz Paroxetine Tablets · DIN 02431793 · $0.3453 Teva-Paroxetine · DIN 02248558 · $0.3453
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-03-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

SERTRALINE HCL

· 49 products · General benefit · strengths: 25mg, 50mg, 100mg · Cap

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS PAXIL (paroxetine hydrochloride) is indicated in adults for the symptomatic treatment of:  Major Depressive Disorder (MDD)  Obsessive-Compulsive Disorder (OCD)  Panic Disorder (with or without agoraphobia)  Social Phobia (Social Anxiety Disorder)  Generalized Anxiety Disorder (GAD)  Posttraumatic Stress Disorder (PTSD) Long-Term Use of PAXIL: Clinical trials have provided evidence that continuation treatment with PAXIL in patients with moderate to moderately severe depressive disorder is effective for at least 6 months (see 14.1 Trial Design by indication, Major Depressive Disorder). The effectiveness of PAXIL in long-term use (i.e. more than 8 weeks for GAD and 12 weeks for other indications) has not yet been established in controlled trials for OCD, panic disorder, social phobia (social anxiety disorder), generalized anxiety disorder and posttraumatic stress disorder. Therefore, the health professional who elects to use PAXIL for extended periods in these indications should periodically re-evaluate the long-term usefulness of the drug for individual patients (see 4.1 Dosing Considerations). 1.1 Pediatrics Pediatrics (< 18 yea… https://pdf.hres.ca/dpd_pm/00067494.PDF PM date: May 4, 1993 Source product: PAXIL TAB 20MG; DIN 01940481; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.